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Abstract
Background:  Antibiotics are recommended for severe acute exacerbation of chronic obstructive
pulmonary disease (AECOPD) admitted to intensive care units (ICU). Serum procalcitonin (PCT) could
be a useful tool for selecting patients with a lower probability of developing bacterial infection, but its
measurement has not been investigated in this population.
Methods:  We conducted a single center prospective cohort study in consecutive COPD patients
admitted to the ICU for AECOPD between September 2005 and September 2006. Sputum samples or
tracheal aspirates were tested for the presence of bacteria and viruses. PCT levels were measured at the
time of admittance, six hours, and 24 hours using a sensitive immunoassay.
Results: Thirty nine AECOPD patients were included, 31 of which (79%) required a ventilator support at
admission. The median [25%–75% interquartile range] PCT level, assessed in 35/39 patients, was: 0.096 μg/
L [IQR, 0.065 to 0.178] at the time of admission, 0.113 μg/L [IQR, 0.074 to 0.548] at six hours, and 0.137
μg/L [IQR, 0.088 to 0.252] at 24 hours. The highest PCT (PCTmax) levels were less than 0.1 μg/L in 14/
35 (40%) patients and more than 0.25 μg/L in 10/35 (29%) patients, suggesting low and high probability of
bacterial infection, respectively. Five species of bacteria and nine species of viruses were detected in 12/
39 (31%) patients. Among the four patients positive for Pseudomonas aeruginosa, one had a PCTmax less
than 0.25 μg/L and three had a PCTmax less than 0.1 μg/L. The one patient positive for Haemophilus
influenzae had a PCTmax more than 0.25 μg/L. The presence or absence of viruses did not influence PCT
at time of admission (0.068 vs 0.098 μg/L respectively, P = 0.80).
Conclusion: The likelihood of bacterial infection is low among COPD patients admitted to ICU for
AECOPD (40% with PCT < 0.1 μg/L) suggesting a possible inappropriate use of antibiotics. Further studies
are necessary to assess the impact of a procalcitonin-based therapeutic strategy in critically ill COPD
patients.
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Introduction
Acute exacerbations are a leading cause of severe respira-
tory failure in chronic obstructive pulmonary disease
(COPD) patients [1]. In this setting, the use of antibiotics
is recommended by the recent guidelines of the European
Respiratory Society (ERS), and French Consensus Confer-
ence [2,3]. However, bacteria are isolated from the respi-
ratory tract of only approximately 50% of patients with
severe acute exacerbation of COPD (AECOPD) [4-6].
Whether this finding represents colonization or infection
is controversial [7-9]. In contrast, a high prevalence of res-
piratory viruses has been reported in severe AECOPD
requiring ventilation [10,11].
In this context, a rapid, specific test to identify lower res-
piratory bacterial infections would be a major advance-
ment, limiting the inappropriate use of antibiotics which
is considered to be a main cause of the spread of antibi-
otic-resistant bacteria [12,13]. Serum procalcitonin levels
are considered to be one of the best biomarkers for pre-
dicting a bacterial infection [14]. The level of circulating
procalcitonin is increased in severe bacterial infections,
but remains fairly low in viral infection and non specific
inflammatory diseases [15,16]. In addition, procalci-
tonin-based therapeutic strategies have been shown to
substantially and safely reduce antibiotic use in patients
with no severe lower respiratory tract infections [17] or
acute exacerbation of COPD [18]. However, studies that
specifically assess this marker in critically ill patients are
scarce.
The aim of the current study was to assess procalcitonin
levels in, and their relationship with viruses and bacteria
in respiratory samples from COPD patients admitted to
the ICU for AECOPD.
Materials and methods
Patients
COPD patients with suspected lower respiratory tract
infection admitted to the medical intensive care unit of
the University Hospital of Caen between September 2005
and September 2006 were assessed for eligibility. Only
those with AECOPD were included in the analysis.
Patients with the presence of infiltrates on chest radio-
graphs taken at admission and suspected of pneumonia,
or exhibiting evidence of other causes of respiratory fail-
ure, were not included in this study.
Definition
We defined COPD according to the Global Initiative for
Chronic Obstructive Lung Disease Guidelines (GOLD)
2005 http://www.goldcopd.org as an FEV1/FVC ratio
(forced expiratory volume in 1 second/functional vital
capacity) of less than 70%, with severity categorized into
mild (FEV1 ≥ 80% of predicted), moderate (FEV1 ≥ 50%
to < 80%), severe (FEV1 ≥ 30% to < 50%) and very severe
(FEV1 < 30%). An AECOPD was defined as "a sustained
worsening of patient's condition, from stable state and
beyond normal day-to-day variations, that is acute in
onset and necessitates a change in regular medication in a
patient with underlying COPD" [19].
AECOPD was considered bacteriologically confirmed in
the presence of a positive Gram stain of respiratory sam-
ples, a pathogen concentration greater than 105cfu/mL in
tracheobronchial aspirations, or a blood culture revealing
a bacterial pathogen in the absence of an extrapulmonary
focus [4]. A culture, indirect immunofluorescence assay
(IFA) or polymerase chain reaction (PCR) assay positive
for viruses was considered evidence for a viral pathogen.
Study design
The protocol of this prospective cohort study was submit-
ted to the local ethics committee. The ethical board
decided that approval was not necessary given the obser-
vational nature of our study. Thus, according to French
legislation at the time of the study, no informed consent
was obtained from the patients. Upon admission to the
ICU, baseline assessment included the severity of COPD
according to GOLD criteria; home oxygen and home non-
invasive ventilation treatment; chronic steroid therapy;
comorbidities such as cigarette smoking, chronic alcohol
abuse, obesity, diabetes mellitus, or chronic cardiovascu-
lar diseases; use of antibiotic therapy and oral steroids for
exacerbations of COPD during the previous 30-day
period; use of antibiotics within 24 hours of ICU admis-
sion; physical examination; chest radiography; and rou-
tine blood tests including c-reactive protein (CRP) at
admission (CRP-H0) and 24 hours later (CRP-H24). In
addition, scoring of disease severity the first day in ICU
was assessed by the Simplified Acute Physiology Score
type II (SAPS II) [20], the Acute Physiology and Chronic
Health Evaluation (APACHE II) score[21], and the Logis-
tic Organ Dysfunction (LOD) score [22]. All patients were
treated according to the recommendations of the French
Consensus Conference [3].
Measurement of serum procalcitonin
All blood samples were centrifuged, decanted, aliquoted,
and frozen at -80°C until analyzed at the end of the study
period. PCT was measured using a sensitive immunoassay
(Kryptor PCT, Brahms, Hennigsdorf, Germany) with a
functional assay sensitivity of 0.06 μg/L, about fourfold
above mean normal levels [23]. The circulating levels of
procalcitonin were sequentially assessed at ICU admis-
sion (PCT-H0), after six hours (PCT-H6), and twenty
fours (PCT-H24) hours. Patients were classified into three
groups based on the probability of bacterial infection
according to the highest procalcitonin level measured
(PCTmax), as previously reported [17,18]: group1 PCT-BMC Infectious Diseases 2008, 8:145 http://www.biomedcentral.com/1471-2334/8/145
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max < 0.1 μg/L indicating an absence of infection, group
2 PCTmax > 0.1 and < 0.25 μg/L indicating a possible
infection and group 3 PCTmax > 0.25 μg/L indicating the
presence of infection.
Microbiological assessment
Upon enrollment, spontaneously expectorated sputum
samples or tracheal aspirates were obtained for Gram
staining and cultures. Bacterial isolation and identifica-
tion was performed with the use of standard techniques.
Sputum or tracheal aspirates were bacteriologically proc-
essed if less than 1% of the observed field contained squa-
mous epithelial cells and more than 25 neutrophils were
observed [24]. A serological diagnostic for antibodies to
Legionella pneumophila was also performed by indirect
immunofluorescence, associated with a detection of
Legionella pneumophila serogroup 1 antigen in urine sam-
ples. In addition, nasal swab or tracheobronchial aspira-
tion was performed in all patients and tested for viruses.
Details of the viral detection methods including culture,
indirect immunofluorescence assay (IFA), and molecular
methods (PCR or RT-PCR), are published elsewhere
[11,25-27]. We tested for the following viruses: parainflu-
enza virus (PIV) 1,2,3, and 4; influenza virus A,B, and C;
respiratory syncytial virus (RSV); metapneumovirus
(hMPV); rhinovirus (RV); coronavirus 229E and OC43;
and, adenovirus (AdV). Chlamydia pneumoniae and Myco-
plasma pneumoniae were also detected by PCR assay.
Statistical analysis
Quantitative and qualitative data were expressed as means
(+/- SD), or median [25%–75% interquartile range] and
percentage (with their 95% CI), respectively. Categorical
variables were compared using the chi-square or Fischer's
exact test as appropriate. Quantitative variables were com-
pared using the Student t-test or the Mann-Whitney non
parametric test as appropriate. Confidence intervals of
percentages were based on normal approximation. The
level of significance was set at 0.05 and all tests were two-
sided. We used EPI-INFO version 6.04 dfr (EPI-INFO,
CDC, Atlanta, GA) for data collection, and EPI-INFO and
SAS version 9.1 (SAS Institute Inc, Cary, NC) for data anal-
ysis.
Results
Baseline characteristics
During the period of the study, 80 COPD patients with
suspected lower respiratory tract infection were admitted
to the ICU, 39 of which had AECOPD (Figure 1). Baseline
characteristics of the AECOPD patients are shown Table 1.
Twenty nine patients (74%) had severe or very severe
COPD. Twenty seven (69%) received home oxygen or
home non-invasive ventilation. Use of antibiotic therapy
or oral steroids for exacerbations of COPD during the pre-
vious 30-day period was reported in 13 and 11 patients,
respectively. Nine patients had received antibiotics within
24 hours of ICU admission. The following treatments
were given at admission: non invasive ventilation (NIV)
in 27 (69%) patients; mechanical ventilation in 6 (15%)
patients, 2 of whom after NIV failure; antibiotics in 33
(85%) patients; systemic steroids in 30 (77%) patients;
and a β2-agonist with inhaled steroids in all patients.
Laboratory measurements
The circulating levels of procalcitonin are shown in Figure
2. The median [25%–75% interquartile range] procalci-
tonin levels at admission (PCT-H0) were 0.096 μg/L
[0.065–0.178], PCT-H6 was 0.113 μg/L [0.074–0.548],
and PCT-H24 was 0.137 μg/L [0.088–0.252]. Procalci-
tonin levels were not different in patients who had
received antibiotics in the month or the 24 hours prior to
ICU admission compared to antibiotic-naive patients
(PCT-H0 0.071 μg/L [0.056–0.189] vs 0.099 μg/L [0.065–
0.178], P = 0.36 and PCT-H0 0.081 μg/L [0.071–0.397] vs
0.103 μg/L [0.062–0.178], P = 0.93, respectively). There
was no association between PCT-H0 levels and the pres-
ence or absence of sputum (PCT-H0 0.106 μg/L [0.072–
0.231] vs 0.085 μg/L [0.062–0.163], P  = 0.65, cough
(PCT-H0 0.083 μg/L [0.068–0.162] vs 0.103 μg/L [0.062–
0.695], P = 0.57, wheezing (PCT-H0 0.083 μg/L [0.057–
0.178] vs 0.103 μg/L [0.075–0.695], P = 0.29, and fever
(ie temperature > 38°C) (PCT-H0 0.081 μg/L [0.068–
0.103] vs 0.098 μg/L [0.059–0.183], P = 0.92). The PCT-
max was < 0.1 μg/L in 14/35 patients (40%), between 0.1
and 0.25 μg/L in 11/35 patients (31%), and > 0.25 μg/L in
10/35 patients (29%). There was no association between
the PCTmax levels and the severity of COPD (P = 0.07).
Patients with PCTmax > 0.25 μg/L were more critically ill:
SAPS II 39 [28–40] vs 27 [24–31] among patients with
PCTmax ≤ 0.25 μg/L, P = 0.005 ; and LOD 5 [3–8] vs 3 [2–
4] among patients with PCTmax ≤ 0.25 μg/L, P = 0.018.
The median CRP level at admission (CRP-H0) was 19 mg/
L [9–60] and CRP-H24 was 21 mg/L [11–34] and was not
significantly higher among those with a PCTmax > 0.25
μg/L (CRP-H0 43 μg/L [11–156] vs 14 [8–24], P = 0.12
and CRP-H24 78 μg/L [11–106] vs 20 [11–26], P = 0.17).
Bacteria and viral findings
Samples were taken at admission in the form of sputum,
tracheobronchial aspirates, or nasal swabs for bacteria
and viral studies in 29 (75%) and 34 (87%) patients,
respectively, but failed because of technical problems in
10 and 5 patients, respectively. Additionally, hemocul-
tures and Legionella diagnostic tests were performed in 37
(95%) and 38 (97%) patients, respectively. According to
our definition, 12 (31%) patients had AECOPD micro-
biologically confirmed. Five species of bacteria (4 Pseu-
domonas aeruginosa, 1 Haemophilus influenzae) and 9
species of viruses (6 rhinovirus, 1 human metapneumov-
irus, 1 parainfluenza 1 and 1 parinfluenza 3) wereBMC Infectious Diseases 2008, 8:145 http://www.biomedcentral.com/1471-2334/8/145
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detected. A co-infection was detected in 2 cases (rhinovi-
rus and Pseudomonas aeruginosa, rhinovirus and Haemo-
philus influenzae). PCT-H0 levels did not differ between
patients with or without AECOPD bacteriologically con-
firmed (PCT-H0 0.081 μg/L [0.062–0.189] vs 0.098 μg/L
[0.065–0.170], P  = 0.75). The four patients with Pseu-
domonas aeruginosa had a PCTmax < 0.25 μg/L. Three of
them were known to be chronically colonized by this
germ and had a PCTmax < 0.1 μg/L. A positive-virus respi-
ratory sample did not influence PCT levels at admission
(PCT-H0 0.068 μg/L [0.062–0.695] vs 0.098 μg/L
[I0.065–0.163], P = 0.80).
Clinical outcome
During their ICU stay, non-invasive ventilation or
mechanical ventilation were performed in 31 patients
(79%). The mean length of non-invasive ventilation,
mechanical ventilation, and ICU stay without ventilation
in days were 4.33 ± 4.54, 2.10 ± 5.55, and 2.13 ± 1.89,
respectively. There was no correlation between these find-
ings and procalcitonin levels (data not shown). The mean
length of ICU stay was 9 ± 7 days. One patient developed
a ventilator-associated pneumonia. He died of COPD-
related respiratory failure seven days after ICU discharge.
In this patient, the PCT levels increased during the first 24
Table 1: Baseline characteristics of all patients and according to the maximum procalcitonin levels measured (PCTmax)
Characteristics AECOPD n = 39* PCTmax<0.1 n = 14 0.1<PCTmax<0.25 n = 11 PCTmax>0.25 n = 10
Age, yr 62 ± 15 54 ± 16 71 ± 10 66 ± 7
Male sex, no.(%) 26(67) 7(50) 8(73) 9(90)
SAPS II score¶ 30 [23–35] 25 [18–30] 31 [26–33] 39 [28–40]
APACHE II score¶¶ 18 [12–23] 13 [9–23] 18 [16–22] 19 [18–26]
LOD score¶¶¶ 4 [2–5] 3 [2–4] 4 [2–4] 5 [3–8]
Comorbidities, no. (%)
Current smokers, 11(28) 4(29) 4(36) 3(30)
Chronic alcohol abuse 8(20) 3(21) 2(18) 2(20)
Obesity 8(20) 2(14) 4(36) 2(20)
Coronary artery disease 4(10) 1(7) 0 3(30)
Hypertensive heart disease 15(38) 4(29) 4(36) 5(50)
Congestive heart disease 2(5) 0 1(9) 0
Diabetes mellitus 13(33) 6(42) 4(36) 3(30)
Chronic Pseudomonas colonization, no. 
(%)
5(13) 3(21) 0 2(20)
Severity of COPD¶¶¶¶, no. (%)
GOLD stage I (mild) 7(18) 4(29) 1(9) 0
GOLD stage II (moderate) 3(8) 1(7) 2(18) 0
GOLD stage III (sever) 3(8) 0 2(18) 1(10)
GOLD stage IV (very sever) 26(67) 9(64) 6(54) 9(90)
Home oxygen, no. (%) 22(56) 8(57) 5(45) 8(80)
Home non-invasive ventilation, no. (%) 5(13) 2(14) 0 2(20)
Oral or inhaled steroid, no. (%) 23(59) 8(57) 7(64) 8(80)
Examination at ICU admission, no. (%)
Dyspnea 39(100) 14(100) 11(100) 10
Cough 17(44) 5(35) 8(73) 4(40)
Sputum 15(33) 5(36) 5(45) 5(50)
Rales 4(10) 1(7) 1(9) 2(20)
Wheezing 30(77) 11(100) 10(90) 7(70)
Body temperature,°C 37.0 ± 0.8 36.7 ± 0.9 37.2 ± 0.5 37.2 ± 0.8
Leucocytes count ((×109/L) 11.5 ± 4.3 9.3 ± 4.1 11.2 ± 4.6 14.2 ± 2.9
CRP-H0 19 [9–60] 13 [8–22] 15 [5–66] 43 [11–156]
CRP-H24 21 [11–34] 21 [11–24] 17 [9–32] 78 [11–106]
Values are given as No.(%), median [25%–75% interquartile range], or mean ± standard deviation
* Levels of procalcitonin (PCT) were assessed in 35/39 patients. PCT is given in μg/L
¶ P = 0.005 for comparing PCTmax > 0.25 μg/L versus PCTmax < 0.25 μg/L; ¶¶ P = 0.08 for comparing PCTmax > 0.25 μg/L versus PCTmax < 
0.25 μg/L; ¶¶¶ P = 0.018 for comparing PCTmax > 0.25 μg/L versus PCTmax < 0.25 μg/L; ¶¶¶¶ P = 0.07 for comparing PCTmax > 0.25 μg/L versus 
PCTmax < 0.25 μg/LBMC Infectious Diseases 2008, 8:145 http://www.biomedcentral.com/1471-2334/8/145
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hours (PCT-H0 0.695 μg/L to PCT-H24 1.388 μg/L). No
patient developed septic shock. Thirty five patients were
discharged from the hospital. Twelve of these patients
(34%) were subsequently hospitalised for AECOPD
within 6 months. PCT-H0 and PCTmax were not predic-
tive of recurrence (data not shown). Four patients died,
three of COPD-related respiratory failure and one of
pneumothorax complicated with cardiac arrest. All had
very severe COPD and a PCTmax > 0.25 μg/L. In univari-
ate analysis, a PCT level > 0.25 μg/L was associated with
mortality (4/10 vs 0/25 deaths among those with a PCT <
0.25 μg/L, P < 0.006).
Discussion
The present study reports procalcitonin levels in critically
ill COPD patients admitted for AECOPD with severe con-
ditions according to the Global Initiative for Chronic
Obstructive Lung Disease criteria. In agreement with pre-
vious reports [17,18], PCT levels (< 0.1 μg/L) could indi-
cate an absence of infection in approximately 40% of
patients. In this sub-group, no bacteria, were detected in
systematic screening, except Pseudomonas aeruginosa in
three patients known to be chronically colonized by this
pathogen. These preliminary results may have important
implications for investigating procalcitonin-based antibi-
otic strategies in severe AECOPD.
Our findings differ from previous studies assessing the
microbiological pattern of AECOPD [4,6,10,28-30],
which reported a higher prevalence of bacteria, varying
from 23% [10] to 72% [4]. Differences in inclusion crite-
ria and diagnostic tests in an absence of respiratory sam-
ples for bacteria detection in a quarter of our patients may
explain this difference. Our rates of virus-positive respira-
The flow of the study measuring procalcitonin in COPD patients Figure 1
The flow of the study measuring procalcitonin in COPD patients. * Procalcitonin (PCT) levels were not assessed in 4 
patients. ** The arrow indicate cross-over between groups.BMC Infectious Diseases 2008, 8:145 http://www.biomedcentral.com/1471-2334/8/145
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tory samples (23%) was consistent with the 22 to 46%
prevalence of respiratory viral infection observed in recent
prospective studies using molecular methods and focus-
ing on COPD patients [10,11,30-32].
We found a PCT level of 0.096 μg/L [0.065–0.178] in
COPD patients admitted to the ICU for severe AECOPD,
consistent with previous studies in this setting (0.096 μg/
L [0.070–0.200] [18]; 0.088 μg/L [0.053–0.161] [33]).
However, in these two large prospective cohorts focusing
on hospitalized AECOPD, less than 10% of patients were
admitted to ICU. According to Stolz et al. [18], PCT levels
were not different between patients pre-treated with anti-
biotics and antibiotic-naive patients, and no association
was found between PCT levels and clinical symptoms or
AECOPD bacteriologically confirmed. In addition, the
proportion of patients with particular levels of PCT was in
accordance with this previous report, suggesting that a
large fraction of patients with low PCT levels (PCTmax <
0.1 μg/L) have a low likelihood of bacterial infection. In
this sub-group, only one pathogen, Pseudomonas aerugi-
nosa, was detected in three patients known to be chroni-
cally colonized by this germ. Whether this finding
represents colonization or infection remains controversial
[7,32,34,35]. This could explain why PCT measurements
failed to identify 3 from 5 patients with AECOPD bacteri-
ologically documented in our study. In one case, rhinovi-
rus was isolated in association with Pseudomonas
aeruginosa, and was considered as the cause of exacerba-
tion. Moreover, we reported that a lower respiratory tract
viral infection did not significantly influence PCT levels in
this setting. In addition, despite our small sample size, we
were able to demonstrate a significant impact of PCT (PCT
> 0.25 μg/L in this cohort) in predicting ICU mortality, as
previously reported in studies focusing on septic shock
[36] and ventilator-associated pneumonia [37].
Box-and-whisker plots representing PCT levels measured at various time Figure 2
Box-and-whisker plots representing PCT levels measured at various time. On the horizontal axis, and for each box-
plot, the legend corresponds to the time of PCT measurement. On the vertical axis, the number corresponds to the PCT lev-
els (μg/L). Each box denotes the middle 50% of the data measured at that time. The lower and upper ends of the box denote 
the 25th and 75th percentile, respectively. The solid black horizontal lines through each box denote the median of the distribu-
tion. The vertical solid black lines (the "whisker") reach out to the 1.5 interquartile range. Circles above the whisker denote 
individual external observations.BMC Infectious Diseases 2008, 8:145 http://www.biomedcentral.com/1471-2334/8/145
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This study had some limitations. The monocentric design
of the study and, the relatively small sample size, as well
as the fact that sputum could not be taken in 10 patients
(25%) for bacteria detection, may limit the interpretation
and relevance of our data. However, PCT assessment was
performed in 90% of patients using technology recog-
nized as the most sensitive, and our findings are consist-
ent with those of previous studies [17,18]. For this reason,
we believe that this study adds useful information about
PCT levels in severe AECOPD requiring an ICU stay and
the likelihood of bacterial infection.
The results reported here may have important implica-
tions for the design of a randomized controlled trial test-
ing procalcitonin-based antibiotic strategies in severe
AECOPD. It has been demonstrated antibiotics have a
marginal efficacy in the treatment of AECOPD, except
among patients with evidence of bacterial infection or
severe exacerbation [38]. Less than 50% of severe
AECOPD may be attributed to bacteria, suggesting the
potential for excessive antibiotic use in this setting [39].
Therefore, serum procalcitonin level may be considered as
a useful tool for predicting bacterial infection, and may
prove useful for selecting patients with a lower probability
of bacterial infection and limit the inappropriate use of
antibiotics, specifically in the ICU setting where antibiotic
use and the emergence of antimicrobial resistance are
highly prevalent [40]. In this context, we speculate that
antibiotic use in the subgroup of severe AECOPD with
lower PCT (< 0.1 μg/L), could be reduced as previously
reported in studies assessing a procalcitonin-based antibi-
otic strategy in non-severe lower respiratory tract infection
[17,18].
Conclusion
Our results support that 40% of patients admitted to ICU
for AECOPD have a low likelihood of bacterial infection
and correlates with a PCT less than 0.1 μg/L, suggesting a
possible inappropriate use of antibiotics. However, fur-
ther studies are necessary: to assess the short-term effect of
a procalcitonin-based therapeutic strategy in critically ill
COPD patients in ICU and secondly, to address the role of
antimicrobial agents in COPD patients in the long-term,
particularly in patients with low PCT levels and bacteria-
positive sputum.
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